Logo image of REAX

REAL BROKERAGE INC/THE (REAX) Stock Fundamental Analysis

NASDAQ:REAX - Nasdaq - CA75585H2063 - Common Stock - Currency: USD

3.84  -0.11 (-2.78%)

After market: 3.85 +0.01 (+0.26%)

Fundamental Rating

4

Taking everything into account, REAX scores 4 out of 10 in our fundamental rating. REAX was compared to 64 industry peers in the Real Estate Management & Development industry. REAX has a great financial health rating, but its profitability evaluates not so good. REAX is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year REAX has reported negative net income.
REAX had a positive operating cash flow in the past year.
REAX had negative earnings in each of the past 5 years.
REAX had a positive operating cash flow in 4 of the past 5 years.
REAX Yearly Net Income VS EBIT VS OCF VS FCFREAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

The Return On Assets of REAX (-15.34%) is worse than 70.31% of its industry peers.
With a Return On Equity value of -47.05%, REAX is not doing good in the industry: 67.19% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -15.34%
ROE -47.05%
ROIC N/A
ROA(3y)-40.11%
ROA(5y)-33.2%
ROE(3y)-83.38%
ROE(5y)-70.74%
ROIC(3y)N/A
ROIC(5y)N/A
REAX Yearly ROA, ROE, ROICREAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

REAX has a worse Gross Margin (9.02%) than 67.19% of its industry peers.
In the last couple of years the Gross Margin of REAX has declined.
REAX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 9.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.17%
GM growth 5Y-6.44%
REAX Yearly Profit, Operating, Gross MarginsREAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

More info and screens

7

2. Health

2.1 Basic Checks

REAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
REAX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, REAX has more shares outstanding
REAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
REAX Yearly Shares OutstandingREAX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
REAX Yearly Total Debt VS Total AssetsREAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

REAX has an Altman-Z score of 19.51. This indicates that REAX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 19.51, REAX belongs to the best of the industry, outperforming 95.31% of the companies in the same industry.
REAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 19.51
ROIC/WACCN/A
WACC9.08%
REAX Yearly LT Debt VS Equity VS FCFREAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 1.23 indicates that REAX should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.23, REAX is in line with its industry, outperforming 48.44% of the companies in the same industry.
REAX has a Quick Ratio of 1.23. This is a normal value and indicates that REAX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.23, REAX perfoms like the industry average, outperforming 51.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.23
REAX Yearly Current Assets VS Current LiabilitesREAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

REAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.00%, which is quite impressive.
The Revenue has grown by 81.31% in the past year. This is a very strong growth!
Measured over the past years, REAX shows a very strong growth in Revenue. The Revenue has been growing by 140.25% on average per year.
EPS 1Y (TTM)65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
Revenue 1Y (TTM)81.31%
Revenue growth 3Y118.22%
Revenue growth 5Y140.25%
Sales Q2Q%76.34%

3.2 Future

Based on estimates for the next years, REAX will show a very strong growth in Earnings Per Share. The EPS will grow by 42.18% on average per year.
REAX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.31% yearly.
EPS Next Y85.43%
EPS Next 2Y45.86%
EPS Next 3Y42.18%
EPS Next 5YN/A
Revenue Next Year47.66%
Revenue Next 2Y31.26%
Revenue Next 3Y26.31%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
REAX Yearly Revenue VS EstimatesREAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B 2B
REAX Yearly EPS VS EstimatesREAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.05 -0.05 0.1 -0.1 -0.15

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

REAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 215.13, the valuation of REAX can be described as expensive.
REAX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. REAX is cheaper than 65.63% of the companies in the same industry.
REAX is valuated expensively when we compare the Price/Forward Earnings ratio to 36.44, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 215.13
REAX Price Earnings VS Forward Price EarningsREAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100 150 200

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, REAX is valued cheaper than 84.38% of the companies in the same industry.
Industry RankSector Rank
P/FCF 18.87
EV/EBITDA N/A
REAX Per share dataREAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates REAX does not grow enough to justify the current Price/Earnings ratio.
REAX's earnings are expected to grow with 42.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.86%
EPS Next 3Y42.18%

More info and screens

0

5. Dividend

5.1 Amount

REAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REAL BROKERAGE INC/THE

NASDAQ:REAX (7/18/2025, 8:08:26 PM)

After market: 3.85 +0.01 (+0.26%)

3.84

-0.11 (-2.78%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners43.16%
Inst Owner Change0%
Ins Owners11.72%
Ins Owner ChangeN/A
Market Cap791.81M
Analysts86
Price Target6.46 (68.23%)
Short Float %1.44%
Short Ratio2.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.53%
Min EPS beat(2)34.64%
Max EPS beat(2)56.43%
EPS beat(4)4
Avg EPS beat(4)52.34%
Min EPS beat(4)34.64%
Max EPS beat(4)67.32%
EPS beat(8)6
Avg EPS beat(8)11.17%
EPS beat(12)8
Avg EPS beat(12)8.1%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)9.39%
Min Revenue beat(2)4.24%
Max Revenue beat(2)14.54%
Revenue beat(4)4
Avg Revenue beat(4)12.6%
Min Revenue beat(4)4.24%
Max Revenue beat(4)26.33%
Revenue beat(8)8
Avg Revenue beat(8)16.57%
Revenue beat(12)12
Avg Revenue beat(12)19.55%
Revenue beat(16)15
Avg Revenue beat(16)20.62%
PT rev (1m)0%
PT rev (3m)-2.5%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)150%
EPS NY rev (1m)72.41%
EPS NY rev (3m)71.43%
Revenue NQ rev (1m)1.18%
Revenue NQ rev (3m)4%
Revenue NY rev (1m)0.94%
Revenue NY rev (3m)4.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 215.13
P/S 0.56
P/FCF 18.87
P/OCF 18.33
P/B 24.18
P/tB 36.99
EV/EBITDA N/A
EPS(TTM)-0.07
EYN/A
EPS(NY)0.02
Fwd EY0.46%
FCF(TTM)0.2
FCFY5.3%
OCF(TTM)0.21
OCFY5.46%
SpS6.88
BVpS0.16
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.34%
ROE -47.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 9.02%
FCFM 2.96%
ROA(3y)-40.11%
ROA(5y)-33.2%
ROE(3y)-83.38%
ROE(5y)-70.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.17%
GM growth 5Y-6.44%
F-Score7
Asset Turnover14.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 85.16%
Cap/Sales 0.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.23
Altman-Z 19.51
F-Score7
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)185.96%
Cap/Depr(5y)132.21%
Cap/Sales(3y)0.18%
Cap/Sales(5y)0.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
EPS Next Y85.43%
EPS Next 2Y45.86%
EPS Next 3Y42.18%
EPS Next 5YN/A
Revenue 1Y (TTM)81.31%
Revenue growth 3Y118.22%
Revenue growth 5Y140.25%
Sales Q2Q%76.34%
Revenue Next Year47.66%
Revenue Next 2Y31.26%
Revenue Next 3Y26.31%
Revenue Next 5YN/A
EBIT growth 1Y57.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year305.8%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2085.78%
FCF growth 3Y133%
FCF growth 5YN/A
OCF growth 1Y1298.09%
OCF growth 3Y131.26%
OCF growth 5YN/A